PledPharma AB

PledPharma and Solasia enter license agreement to develop and commercialize PledOx(r) in Asia

PLEDPHARMA PRESENTS ADDITIONAL RESULTS FROM A PHASE IIB STUDY WITH PLEDOX® AT THE SCIENTIFIC CONFERENCE MASCC

Interim report first quarter 2015

PLEDPHARMA PRESENTS TOP-LINE RESULTS FROM ITS PHASE IIb STUDY – PLEDOX(r) REDUCES NERVE DAMAGE IN CONJUNCTION WITH CHEMOTHERAPY BY 43 PERCENT

PLEDPHARMA PRESENTS TOP-LINE RESULTS FROM ITS PHASE IIb STUDY – PLEDOX® REDUCES NERVE DAMAGE IN CONJUNCTION WITH CHEMOTHERAPY BY 43 PERCENT

Year-end report 2014

PledPharma’s rights issue oversubscribed by 34 percent

More than 50 percent of the owners confirm subscription commitments in PledPharma’s planned rights issue

PledPharma AB – Interim report third quarter 2014

PledPharma presents a new project against acetaminophen-induced poisoning, aimed to be financed by a rights issue

The PLIANT study is fully recruited and the final futility analysis approved

Information video about PLIANT study available

PledPharma awarded Nordic Star of the Year

The second futility analysis in the PLIANT study completed and approved

PledPharma AB – Interim report second quarter 2014

Positive data from an additional 5 patients in the first part of the PLIANT study

Futility analysis in PLIANT study completed and approved by the DSMB

Rights issue in PledPharma oversubscribed

PledPharma AB (publ) Interim report first quarter 2014

Go-ahead for PledPharma to also include Avastin patients in Part 2 of the PLIANT study

PledPharma AB (publ) issues new shares

Year end report 2013

PledPharma brings forward publication date for full year report 2013

Positive data from the first part of the PLIANT study

Positive data from the first part of the PLIANT study

First patient treated in part 2 of the PLIANT-study

Nomination Committee for the 2014 Annual General Meeting in PledPharma AB

Go-ahead for PledPharma to start part 2 of the PLIANT study

Interim Report Third Quarter 2013

The sixth patient in the first part of the PLIANT-study approved for continued dosing